Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amneal Targets Up to 50 Launches, But Fears Diminishing Returns

Executive Summary

Amneal has a solid roster of generics lined up for introduction in the US this year; but challenging market dynamics are forcing the company to reassess the commercial potential of these launches.

You may also be interested in...



Lyrica Rivals Are Rolled Out In The US

Several generic rivals to Pfizer’s Lyrica have hit the US market following the anti-seizure and pain brand’s loss of exclusivity.

Amneal’s Shares Slump On Slashed Earnings Outlook and Cost-Cutting Plan

Investors have downgraded their valuation of Amneal after the US firm blamed a highly competitive local generics market for slashing its earnings forecast. To improve its competitiveness, Amneal is planning to cut 550 jobs and close two plants.  

If Amneal Goes Global Again, It Intends To Go Big

Having just sold off relatively small operations in the UK and Germany, Amneal would look for large-scale deals if it were to expand again beyond its US powerbase. The US generics and specialty brands company is also looking to expand its injectables business and is considering a move into biosimilar insulins.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB140149

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel